European Translational Information & Knowledge Management Services (eTRIKS)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • No disease focus

Abstract

European Translational Information & Knowledge Management Services (eTRIKS) aims to create and run an open, sustainable, research informatics and analytics platform for use by drug development projects with knowledge management (KM) needs. eTRIKS provides associated support, expertise, and services to ensure that users gain the maximum benefit from the platform. The project’s starting point will be tranSMART, an open-source platform that is already being applied successfully in the Innovative Medicine’s Initiative’s (IMI’s) severe asthma project U-BIOPRED. The eTRIKS team will provide a suite of support services covering the whole translational research project life cycle, including business analysis, platform development, curation and hosting support, standards development, and ethics consultation. The expected duration of the project is 60 months.

Mission

The main mission of eTRIKS is to deliver KM solutions for translational and collaborative research projects. eTRIKS is a collaborative project focused on increasing the efficiency of translational research by reducing the cost of translational research data and KM, enabling non-statisticians to perform exploratory analyses and facilitating cross-study analyses.

eTRIKS aims to build a KM platform and community that will:

Consortium History

Jan. 10, 2013: Project start date
2014: First community meeting on Translational Research Knowledge Management in Action in Barcelona, Spain

Structure & Governance

The eTRIKS governance structure integrates the European Federation of Pharmaceutical Industries and Associations (EFPIA) and academic and small to medium-sized enterprise (SME) members into the decision-making process. Several working groups help with each project initiated by eTRIKS and report to the eTRIKS Executive Committee. They are platform deployment, data standards, platform development, curation and analysis, ethics, and community and outreach.

Financing

This project is funded by IMI, a public-private partnership between the European Union (EU) and the EFPIA, resources of which are composed of financial contributions from the EU Seventh Framework Programme and in kind contributions of EFPIA members. Large pharmaceutical companies participating in IMI projects do not receive IMI funding. IMI has contributed €10.3 million, EFPIA has contributed
€10.3 million in kind (includes non-EU contribution of €0.6 million), and other sources have contributed   €3.1 million (includes €1 million from ID Business Solutions Limited), for a total cost of €23.7 million).

Intellectual Property

The IMI intellectual property (IP) policy governs the IP aspects of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

According to IMI’s IP policy, the participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The project agreement shall include a description of the material, which must be disseminated in accordance with the IP policy and referenced in the grant agreement. If the participants do not disseminate within such time periods without good reason, then the Executive Office has the right to disseminate such results in a manner consistent with the grant agreement.

Impact/Accomplishment

By creating a single, open-source platform that meets industry needs while remaining affordable for public partners, eTRIKS will deliver considerable cost savings for public-private partnerships that use it. Furthermore, by ensuring the consistent implementation of format and content standards, eTRIKS will facilitate the reuse of data (with appropriate governance) to study new issues and accelerate the development of new drugs for patients.

In the longer term, eTRIKS plans to develop a business model that will allow the platform to continue to operate after the initial IMI funding period. The partners also hope that their work will result in the formation of an active international translational research analytics and informatics community.

A number of items have been published on the eTRIKS blog. The link to the blog is  http://www.etriks.org/category/blog/ 

Points of Contact

Ian Dix
AstraZeneca
phone: +44 7748 761282
email: ian.dix@astrazeneca.com

Yike Guo
Imperial College London
phone: +44 207 594 8182
email: y.guo@imperial.ac.uk

Sponsors & Partners

AstraZeneca AB, Sodertalje, Sweden

Bayer Pharma AG, Berlin, Germany

BioSci Consulting

CDISC Europe Foundation, Woluwe-Saint Lambert, Belgium

Centre National de la Recherche Scientifique, Paris, France

Eli Lilly, Basingstoke, UK

F. Hoffmann-La Roche AG, Basel, Switzerland

GlaxoSmithKline Research and Development Ltd., Brentford, UK

H. Lundbeck A/S, Valby, Denmark

ID Business Solutions Limited

Imperial College of Science, Technology and Medicine, London, UK

Janssen Pharmaceutica NV, Beerse, Belgium

Merck KGaA, Darmstadt, Germany

Pfizer Limited, Sandwich, UK

Sanofi-Aventis Research and Development, Chilly-Mazarin, France

University of Luxembourg, Luxembourg, Luxembourg


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.